79.95 0.00 (0.00%)
After hours: 5:51PM EDT
|Bid||79.92 x 300|
|Ask||79.99 x 6700|
|Day's range||79.55 - 81.21|
|52-week range||63.76 - 86.27|
|PE ratio (TTM)||8.68|
|Dividend & yield||2.08 (2.56%)|
|1y target est||N/A|
Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates. Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website.
The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.
Nimbus Therapeutics, which struck a $1.2 billion deal to sell a drug program focused on liver diseases to Gilead Sciences Inc. last year, has formed a new immunology collaboration with Celgene Corp.
Looking for some investments in the healthcare sector that aren't priced at a high premium? Allergan, Gilead Sciences, and DaVita are an excellent place to start.
Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).
The Trump Administration threw its support behind a public-private partnership with 11 drug companies to advance a new class of drugs that uses the body's immune system to fight cancer. The five-year collaboration ...
AbbVie's yield is higher than those of its peers, but expiring patents on the company's top-selling drug does make it a bit riskier than other dividend payers in healthcare.
Leerink's Geoffrey Porges and Bradley Canino recently reviewed the Hepatitis C (HCV) market, and increased their price targets on Gilead (GILD) and AbbVie (ABBV) They write that both stocks are likely to enjoy a duopoly for HCV "in perpetuity," as other competitors like Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ) and Merck (MRK) have scaled back their efforts. More from the note: After the recent announcements from JNJ (returning the rights to Achillion’s [ACHN] HCV NS5a inhibitor) and Merck (halting further development of uprifosbuvir), and the prior discontinuation of further investment into HCV at Bristol Myers after their unsuccessful investment into Inhibitex, it is now clear that the HCV category will come down to only two committed participants, Gilead and AbbVie.
Gilead Sciences (GILD) entered the year on a downswing, but its stock has since reversed that underperformance and now sits near a 52-week high. It's not that much has changed: Hepatitis C is still a big question mark and its HIV business could be threatened by competition. Oppenheimer's Hartaj Singh and Emma Nealon liken Gilead Sciences to a supertanker trying to accelerate.
Today, Gilead Sciences (GILD) announced that a Phase 3 trial of switching to Bictegravir-F-Taf for HIV patients was completed with positive safety results, following a July announcement about data that demonstrated that it didn't work better than what its intended to replace. In a press release, Gilead explains why it considers the results a big deal: “These data demonstrate the potential of BIC/FTC/TAF to match the efficacy of a boosted protease inhibitor regimen while also offering a high barrier to resistance and fewer interactions with other drugs,” said Eric Daar, MD, Chief of the Division of HIV Medicine at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and lead author of Study 1878. “The findings, along with data from three other Phase 3 studies in both treatment-experienced and treatment-naïve patients, suggest that the investigational regimen of BIC/FTC/TAF may be appropriate for a broad range of people living with HIV.” Leerink's Geoffrey Porges and Bradley Canino call the treatment "one of the most important products in our revenue outlook for Gilead." They explain why: [We] forecast the first sales of the combination in Q1 from the US and Q3 from Europe.
Over the past few years, consolidation has become an important trend in nearly every major global industry. To celebrate this, we've compiled our list of the most important M&As of 2017!
With Merck (MRK) discontinuing the development of two HCV candidates, here's a look at what to expect from the remaining key players in the HCV market.
When Gilead Sciences (GILD) announced its acquisition of Kite Pharma (KITE), every company that had exposure to CAR-T --a type of cancer therapy that could allow for the creation of personalized drugs--got ...
Merck (MRK) is discontinuing the development of two of its hepatitis C (HCV) programs - MK-3682B and MK-3682C - as the HCV market is becoming extremely crowded.
Kymriah is among a new wave of therapies that use a patient's own cells as medicine. But this historic treatment comes with a historic price.